Company name OphtiMed$_{Rx}$ * Website https://www.ophtimedrx.com/ *

CEO name Dana Rabinovich *

CATEGORY: Biotech/Pharma
SESSIONS

- Illuminating the Path; Innovations and Challenges in Eye Care
- Aging Redefined: Breakthroughs in Science and Technology in Longevity
- Executive Summary / Investment Rational

  OphtiMed$_{Rx}$ is developing OM-301, a first-in-class anti-senescence drug, for the treatment dry AMD, a leading cause of vision loss with no approved treatments to prevent vision loss. Backed by a worldclass team and robust preclinical data, the company addresses a multibillion-dollar unmet need and aims to redefine the paradigm of AMD treatment.

- Core Technology

  OM-301 is a first-in-class innovative anti-senescence drug that targets cellular aging. In preclinical models, OM-301 has shown a robust protective effect against retinal cell senescence, with evidence of halting retinal degeneration and improving cellular health, this unique mechanism of action positions OM-301 as a leading candidate in the dry AMD treatment space.

- Product Profile/Pipeline

  OM-301 is in late-stage preclinical development, with plans to enter clinical trials following IND-enabling studies. The company aims to secure a strategic partner for late-stage clinical development and commercialization. Key milestones include IND submission and FIH trials. Potential collaborations include licensing agreements and co-development partnerships.

- Business Strategy

  Following proof of concept in humans, OphtiMed$_{Rx}$ plans to establish a strategic partnership or out-license OM-301 with a major pharmaceutical company to support late-stage clinical development and global commercialization, optimizing the pathway to market. Revenue will be generated through licensing agreements, milestone payments, and royalties from pharmaceutical partners, especially during late-stage clinical and commercial phases.

- What's Next?

  OphtiMed$_{Rx}$ will execute IND-enabling studies before initiating FIH trials. Organizational plans include securing additional funding and expanding collaborations with industry partners. The next financial goal is completing a $4M seed round to complete the preclinical work, followed by a $13M round to support phase I trials and regulatory progress.